<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132934</url>
  </required_header>
  <id_info>
    <org_study_id>DIM-05762-004</org_study_id>
    <nct_id>NCT04132934</nct_id>
  </id_info>
  <brief_title>Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN</brief_title>
  <acronym>DIA-RAMADAN</acronym>
  <official_title>Observational Study Program Assessing Effectiveness and Tolerability of Gliclazide MR 60mg in Patients With Type 2 Diabetes Fasting During RAMADAN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Servier Affaires Médicales</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Servier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to assess effectiveness and tolerability of
      gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific
      and Middle East/North Africa
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Actual">October 4, 2019</completion_date>
  <primary_completion_date type="Actual">October 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with at least one Hypoglycemia event</measure>
    <time_frame>up to 5 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">1200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with type 2 diabetes observing fast during Ramadan
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent obtained before any trial-related activities

          -  Male or female type 2 diabetic patients aged &gt;18 years

          -  Patients with controlled or suboptimal controlled type 2 diabetes

          -  Patients with experience in SMBG controlling using glucometer

          -  Patients who are willing to fast during Ramadan

          -  Patients already treated with Gliclazide MR 60mg

        Exclusion Criteria:

          -  Insulin therapy requirement

          -  Severe liver or renal failure

          -  HbA1c ≥ 9%

          -  Contraindication to gliclazide according to SmPC

          -  Pregnancy or breast feeding

          -  Previous experience of severe or repeated hypoglycemia events without triggered factor
             within the previous year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Servier Affaires Medicales</name>
      <address>
        <city>Suresnes</city>
        <zip>92284</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/32330510</url>
    <description>A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN.</description>
  </link>
  <results_reference>
    <citation>Hassanein M, Al Sifri S, Shaikh S, Abbas Raza S, Akram J, Pranoto A, Rudijanto A, Shaltout I, Fariduddin M, Mohd Izani Wan Mohamed W, Al Awadi F, Alessa T; DIA-RAMADAN study investigators. A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN. Diabetes Res Clin Pract. 2020 May;163:108154. doi: 10.1016/j.diabres.2020.108154. Epub 2020 Apr 21.</citation>
    <PMID>32330510</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

